DNLI Q3 2017 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$22M

EPS (Diluted)

$-0.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$210M

Total Liabilities

$17M

Stockholders' Equity

$193M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$22M	-$26M	+13.0%
Net Income	-$22M	-$31M	+28.6%